Steroids injection for alopecia
Reading File
Finding Sources
Searching PubMed
"alopecia areata" AND "intralesional corticosteroid"
Finding Sources
Searching PubMed
"alopecia areata" AND "intralesional" AND corticosteroid
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative dermatology textbooks. Here is a complete, well-sourced answer:
Intralesional Steroid Injections for Alopecia
Indications
Intralesional corticosteroid injection is the treatment of choice for localized alopecia areata - particularly for cosmetically conspicuous patches such as those in the frontal hairline or involving the eyebrows. It is also used in:
- Alopecia areata (patchy, localized)
- Frontal fibrosing alopecia (FFA) - a scarring alopecia
- Lichen planopilaris (scarring alopecia)
(Andrews' Diseases of the Skin, p. 3401; Katzung's Basic & Clinical Pharmacology, 16th Ed.)
Drug of Choice
Triamcinolone acetonide is the most widely used agent. Other options include triamcinolone diacetate, triamcinolone hexacetonide, and betamethasone acetate-phosphate.
When injected intradermally, these relatively insoluble suspensions remain in place and are gradually released over 3-4 weeks, providing sustained local immunosuppression. - Katzung's Basic & Clinical Pharmacology
Technique and Dosing
| Parameter | Recommendation |
|---|---|
| Drug | Triamcinolone acetonide |
| Concentration | 2.5-10 mg/mL (scalp); 2.5-5 mg/mL (FFA/LPP) |
| Volume per site | ~0.1 mL per injection point |
| Injection plane | Mid to deep dermis (intradermally or superficial subcutaneous) |
| Spacing | Injection sites ~1 cm apart |
| Max dose per session | 10-20 mg total per session in adults |
| Per-site limit | 1 mg per treatment site (to reduce atrophy risk) |
| Frequency | Every 3-4 weeks |
(Dermatology 2-Volume Set 5e; Andrews' Diseases of the Skin; Katzung's)
- Higher concentrations (>10 mg/mL) and larger volumes carry greater risk of dermal atrophy.
- In frontal fibrosing alopecia, lower doses (2.5-5 mg/mL) are preferred. - Fitzpatrick's Dermatology
Important Safety Warnings
- Retinal artery embolization - injection under high pressure or through a small-bore syringe increases the risk. Use low pressure and appropriate needle gauge, especially near the temporal and periorbital areas.
- Local skin atrophy - most common adverse effect; risk rises with higher concentrations, larger volumes, and superficial injection. Keep dose per site to ≤1 mg.
- Hypopigmentation - particularly noticeable in darker skin types.
- HPA axis suppression - rare with intralesional use but possible with frequent, high-dose sessions over large areas.
Role vs. Other Treatments
| Treatment | Notes |
|---|---|
| Intralesional TA (first-line) | Best for localized/patchy AA; eyebrows; frontal hairline |
| High-potency topical steroids | Safer but less reliable than injections |
| Oral pulse corticosteroids (e.g., methylprednisolone 500 mg/day x3 days monthly) | For rapidly progressive or widespread disease; >60% response in patchy AA |
| JAK inhibitors (baricitinib, ritlecitinib - FDA approved) | Excellent for severe/extensive AA; first-line for alopecia totalis/universalis |
| Contact sensitizers (DPCP, DNCB) | For refractory cases |
| Topical minoxidil | May be combined as adjunct |
(Andrews' Diseases of the Skin; Dermatology 2-Volume Set 5e)
Mechanism
Alopecia areata is autoimmune - CD8+ cytotoxic T cells breach the "immune privilege" of the hair follicle bulb, driven by IFN-γ and IL-15. Corticosteroids suppress this peribulbar lymphocytic infiltrate, restoring the immune privilege and allowing hair regrowth. - Fitzpatrick's Dermatology, Andrews' Diseases of the Skin
Prognosis Note
Spontaneous remission is common in limited disease - in one series, all but 4 of 63 patients had spontaneous regrowth by 1 year. This means anecdotal success reports for any treatment must be interpreted cautiously. Predictors of a good response to treatment include: disease duration <6 months, onset age <10 years, and multifocal (not ophiasic) pattern. - Andrews' Diseases of the Skin
A recent 2025 PubMed review (PMID 40026917) confirms intralesional corticosteroids remain a key treatment modality alongside the newer FDA-approved JAK inhibitors (baricitinib, ritlecitinib), which are now preferred for moderate-to-severe disease.
Side effects
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Here is a focused breakdown of all side effects of intralesional steroid injections for alopecia, organized by frequency and severity:
Side Effects of Intralesional Steroid Injections for Alopecia
Local Side Effects (Most Common)
1. Dermal/Subcutaneous Atrophy
The most common and clinically significant local complication. Presents as a depressed, sunken area at the injection site.
- Caused by inhibition of fibroblast activity and reduction of collagen/ground substance
- Risk is higher with: higher concentrations (>10 mg/mL), larger volumes, injection too deep into fat (instead of dermis), and frequent sessions
- Generally reversible over months to years
- Prevention: Use the minimum effective concentration (2.5-5 mg/mL on scalp), inject into mid-dermis not subcutaneous fat, limit to ≤1 mg per site - Andrews' Diseases of the Skin
2. Hypopigmentation
- Localized depigmentation at injection sites, more noticeable in darker skin types (Fitzpatrick types III-VI)
- Can also appear as linear hypopigmented streaks if the drug migrates along lymphatic channels
- Usually temporary but may persist for months
3. Lymphatic Migration
- Injected corticosteroid can travel along lymphatic channels away from the target site
- Results in linear, atrophic, hypopigmented, hairless streaks extending beyond the injection site
- May take years to resolve
- Prevented by injecting directly into the lesion (not fat) and using minimal volumes - Andrews' Diseases of the Skin
4. Pain / Discomfort at Injection
- Burning or stinging sensation during injection, especially in the scalp (which is pain-sensitive)
- Can be minimized by: diluting with lidocaine, using a fine-gauge needle (30G), injecting slowly, using topical anesthetic beforehand, or using a Dermojet/needle-free injector
5. Scalp Tenderness / Post-injection Soreness
- Usually mild and resolves within 24-48 hours
6. Telangiectasia
- Small dilated blood vessels at the injection site, particularly with repeated injections in the same area
7. Folliculitis / Infection
- Rare; standard aseptic technique prevents this
Serious but Rare Complications
Retinal Artery Embolization (Vision Loss)
- A rare but catastrophic complication, particularly relevant for scalp and temporal/periorbital injections
- Occurs when steroid particles are inadvertently injected under high pressure into a vascular channel, retrograde travel reaching the ophthalmic or retinal circulation
- Risk factors: high injection pressure, small-bore syringe, injections near temporal vessels or eyebrows
- Prevention: Use low pressure, large-bore needle (e.g., 27-30G), aspirate before injecting, avoid high-velocity injection devices near the temporal area - Andrews' Diseases of the Skin
Systemic Side Effects (Uncommon at Typical Doses)
At standard intralesional doses (total 10-20 mg per session), systemic absorption is low. However, with repeated frequent sessions or high cumulative doses:
| Effect | Details |
|---|---|
| HPA axis suppression | Transient cortisol suppression possible; usually subclinical at standard doses |
| Cushing features | Extremely rare with intralesional use alone |
| Glucose elevation | Relevant in diabetic patients; monitor blood sugar |
| Elevated intraocular pressure | Rare with scalp injections; more relevant near periorbital area |
- Katzung's Basic & Clinical Pharmacology 16th Ed.; Andrews' Diseases of the Skin
How to Minimize Side Effects - Summary
| Risk | Mitigation |
|---|---|
| Atrophy | Use 2.5-5 mg/mL, inject into dermis not fat, ≤1 mg/site |
| Hypopigmentation | Warn darker-skinned patients; use lower concentration |
| Lymphatic spread | Inject directly into lesion, avoid excess volume |
| Retinal embolism | Low-pressure injection, avoid small-bore syringe near temporal/eye areas |
| Systemic effects | Keep total dose per session ≤20 mg; space sessions ≥3-4 weeks apart |
| Pain | 30G needle, lidocaine dilution, topical anesthetic |
Bottom line: Intralesional triamcinolone acetonide at 2.5-5 mg/mL with proper technique has a favorable safety profile. Dermal atrophy and hypopigmentation are the main practical concerns, and both are largely preventable with correct injection depth, concentration, and dose per site.
This is a shared conversation. Sign in to Orris to start your own chat.